Abstracts Archive - Page 358 of 1683 - ATC Abstracts

2020 American Transplant Congress
Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation
K. Bzeizi, A. Albenmousa, M. Shawkat, W. Alhamoudi, S. Alabad, R. Troisi, D. Broering
KFSHRC, Riyadh, Saudi Arabia
*Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…
2020 American Transplant Congress
The Association of Body Weight Gain/Change and Hepatocellular Carcinoma Recurrence after Liver Transplant
O. Ahmed¹, M. Sauer¹, N. Vachharajani¹, S. H. Chang², Y. Park², A. S. Khan¹, W. C. Chapman¹, M. B. Doyle¹
¹Department of Surgery, Washington University School of Medicine, St Louis, MO, ²Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO
*Purpose: Functional recovery in liver transplant recipients is commonly confounded by weight changes relating to various aspects of liver disease such as cachexia, ascites and…
2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
M. L. Goldman¹, K. Zhou², J. L. Dodge¹, F. Yao¹, N. Mehta¹
¹Department of Medicine, UCSF, San Francisco, CA, ²Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
2020 American Transplant Congress
Is the Survival Impacted by Multiple Cancer after Liver Transplantation? A Retrospective French National Multicentric Study between 1993-2013
M. Altieri
Chu Caen, Caen, France
*Purpose: Introduction: Despite the great progress made in recent decades, post-liver transplant de novo cancers is one of the leading causes of late complications and…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Twin Pregnancies after Liver Transplantation
L. A. Coscia¹, A. Yusuf¹, S. Rao², S. Constantinescu³, M. J. Moritz⁴
¹Transplant Pregnancy Registry International, Philadelphia, PA, ²Medicine, University of Virginia Heath System, Charlottesville, VA, ³Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ⁴Surgery, Lehigh Valley Health Network, Allentown, PA
*Purpose: The purpose of this study is to describe twin pregnancy outcomes in female liver transplant recipients.*Methods: Data were collected by the Transplant Pregnancy Registry…
2020 American Transplant Congress
Risk Factors Associated with Hepatic Artery Thrombosis in the Modern Era
M. Krach, A. Kernodle, P. Chiang, D. Segev, A. Massie, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Historically, hepatic artery thrombosis (HAT) has been associated with certain risk factors, such as donor age, cold ischemia time, and split grafts; it is unclear…
2020 American Transplant Congress
Risk Factors for Hepatic Artery Thrombosis: A Single Center Study with Multiple Surgeons
M. Fitzsimons¹, M. Bindal², J. Buggs³, D. Patino⁴, E. Rogers³, A. Kumar¹, A. Lu³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴University of Tampa, Tampa, FL
*Purpose: Hepatic Artery Thrombosis (HAT) is an uncommon complication after liver transplant, but its occurrence can lead to significant and fatal outcomes. Our objective was…
2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, J. McVey¹, D. Firl², Y. Inaba³, C. D. Kwon¹, K. Hashimoto¹, F. Aucejo¹
¹The Cleveland Clinic, Cleveland, OH, ²Duke University, Durham, NC, ³Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…
2020 American Transplant Congress
Evaluation of Leukopenia and Neutropenia Incidence, Treatment, and Clinical Response in Kidney and Liver Transplant Recipients
H. Kutzler, T. Webb, R. Cecere, D. O'Sullivan, P. Sheiner
Hartford Hospital, Hartford, CT
*Purpose: The purpose is to evaluate incidence, recurrence, therapy modifications, and complications of leukopenia and neutropenia (LN) in kidney (KTR) and liver transplant (LTR) recipients.*Methods:…